Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belantamab - GSK

Next Previous
X
Search
Drug Profile

Belantamab - GSK

Alternative Names: bela; GSK-2857914; GSK2857914 (naked antibody without MMAF toxin)

Latest Information Update: 25 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I Systemic lupus erythematosus

Most Recent Events

  • 03 Jun 2024 Phase-I clinical trials in Systemic lupus erythematosus in USA (IV) (NCT06413511)
  • 14 May 2024 GlaxoSmithKline plans a phase I trial for Systemic lupus erythematosus in USA (IV, Infusion) (NCT06413511)
  • 16 Feb 2023 GlaxoSmithKline plans the phase I/II DREAMM-20 trial for Multiple myeloma (Monotherapy, Combination therapy, Second-line therapy or greater) (Parenteral) (NCT05714839)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top